For many years, people diagnosed with pancreatic cancer had very low chances of living long. Between 2015 and 2021, almost 97% of patients with advanced disease died within five years.
Pancreatic cancer is hard to catch early because there are no good screening tests and early symptoms are often invisible. By the time signs such as yellow skin (jaundice) or stomach pain appear, the cancer usually has spread.
Doctors who treat the disease have long needed better medicines. The main problem is that more than 90% of pancreatic tumors are driven by a faulty gene called KRAS. This gene acts like a switch that tells cells to grow. When KRAS is mutated, the switch stays stuck on, forcing cancer cells to multiply nonstop.
Why KRAS Was Called “Undruggable”
Traditional treatment for advanced pancreatic cancer has been chemotherapy. Chemo drugs attack fast‑growing cells, but cancer cells often learn to resist them. Because KRAS does not have obvious pockets for drugs to grab, scientists thought it could not be targeted directly.
Without a way to hit KRAS, patients have had to rely on harsh chemotherapy that also harms healthy tissue, leading to many side effects.
Introducing Daraxonrasib
A new medicine named daraxonrasib is changing the story. It is taken by mouth every day. Instead of sticking directly to KRAS, it binds to a helper protein called cyclophilin A, which then connects to KRAS and turns the faulty switch off.
In a large Phase 3 study with 500 patients who had already received other treatments, daraxonrasib increased the average overall survival from about 7 months to more than 13 months—almost a two‑fold improvement. The drug cut the risk of death by roughly 60% compared with standard chemotherapy.
The most common side effect was a skin rash, affecting over 80% of participants. Some patients also experienced mouth sores, diarrhea, nausea, or vomiting. However, fewer people stopped treatment because of severe side effects, and many reported better quality of life and less pain.
What Comes Next?
Now the drug is awaiting review by health‑regulators such as the U.S. Food and Drug Administration. If approved, it could reach clinics within months, especially since therapies that show big survival gains often receive fast‑track review.
This success suggests that other “undruggable” cancers might also be treatable with similar targeted approaches. Future studies may combine KRAS inhibitors with other medicines to keep tumors from becoming resistant.
